Trial · NCT07334301
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
NCT07334301, Phase 1, Phase 2, Recruiting, University of Birmingham
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Multi-Arm, Platform Trial For Relapsed Neuroblastoma. Trials, record NCT07334301. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07334301
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
- NCT number
- NCT07334301
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 160 participants, estimated
- Lead sponsor
- University of Birmingham
- Conditions
- Relapsed Neuroblastoma
- Interventions
- Bevacizumab, Dinutuximab beta, Irinotecan (drug), Topotecan, Temozolomide (TMZ), Temozolomide (TMZ)
- First posted
- 2026-01-12
- Last updated
- 2026-01-12
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival time | From date of randomization until the date of first documented failure event (progression or death), assessed up to 60 months. | • Progression-Free Survival time (as per International Neuroblastoma Response Criteria (PD Progressive disease, SD Stable disease, MR Minor response, PR Partial response, CR Complete response) INRC 2017) - for Tier 1 (randomised comparison) |
| Primary | Occurrence of dose-limiting toxicities to definition of a safe and tolerable combination regimen | From date of randomization until the date of first documented failure event (progression or death), assessed up to 60 months. | Tier 2 (dose expansion-confirmation cohorts): Definition of a safe and tolerable (i.e. \</= 3 dose-limiting toxicities) combination regimen |
| Secondary | Best objective response | At the end of the last treatment cycle, up to 12 cycles (each cycle is 21 days) | Best objective response (complete and partial response) per the INRC 2017 during trial treatment (12 cycles) |
| Secondary | Clinical benefit | At the end of the last treatment cycle, up to 12 cycles (each cycle is 21 days) | Clinical benefit (complete, partial and minor response and stable disease) per the INRC 2017 (International Neuroblastoma Response Criteria (PD Progressive disease, SD Stable disease, MR Minor response, PR Partial response, CR Complete response)) |
| Secondary | Time response to progression | From date of response (Complete Response, Partial Response or Minor Response as per INRC) until the date of first documented failure event (progression or death), assessed up to 60 months. | Time between Response to Progression (i.e. Duration of Response) for patients who respond |
| Secondary | Overall Survival time | From date of trial entry until the date of first documented failure event (progression or death), assessed up to 60 months. | Overall Survival time |
| Secondary | Quality of life of patients measured by Peds-QL questionnaires | At the end of the last treatment cycle, up to 12 cycles (each cycle is 21 days) | Quality of life of patients measured by Pediatric Quality of Life Inventory (Peds-QL) questionnaires. 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher PedsQL 3.0 scores indicate better Health Related Quality of Life (HRQOL). |
| Secondary | Incidence and Severity of AEs | From date of trial entry until the date of last follow up, assessed up to 60 months. | Incidence and Severity of AEs |
| Other | Quality of life of caregivers measured by Peds-QL questionnaires | At the end of the last treatment cycle, up to 12 cycles (each cycle is 21 days) | Quality of life of caregivers measured by Pediatric Quality of Life Inventory (Peds-QL) questionnaires. 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher PedsQL 3.0 scores indicate better Health Related Quality of Life (HRQOL) |
| Other | Correlation between objective response using INRC 2017 and PFS/OS | At the end of the last treatment cycle, up to 12 cycles (each cycle is 21 days) | Correlation between objective response using INRC 2017 and PFS/OS |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 8336186 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07334301
GET https://conductscience.org/api/trials/v1/NCT07334301/registered